[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.92.239.248. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

February 1, 2017, Vol 2, No. 2, Pages 117-230

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2017;2(2):117. doi:10.1001/jamacardio.2016.3629
Viewpoint

Educating Cardiovascular Fellows in the Contemporary EraDeveloping Competent Cardiologists

Abstract Full Text
JAMA Cardiol. 2017;2(2):119-120. doi:10.1001/jamacardio.2016.4084

This Viewpoint explores the major differences in training between the past and the present for cardiovascular fellows and addresses the challenges that they face now and in the future.

Editorial

Leading on Payment and Delivery Reform in Cardiology

Abstract Full Text
JAMA Cardiol. 2017;2(2):121-123. doi:10.1001/jamacardio.2016.4028

Association Between Human Immunodeficiency Virus Infection and Cardiovascular DiseasesFinding a Solution to Double Jeopardy

Abstract Full Text
open access
JAMA Cardiol. 2017;2(2):123-124. doi:10.1001/jamacardio.2016.5177

Troponin Assessment in Heart Failure With Preserved Ejection FractionTime to Get With the Guidelines

Abstract Full Text
JAMA Cardiol. 2017;2(2):125-126. doi:10.1001/jamacardio.2016.4840
Original Investigation

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa InhibitorsAn Exploratory Analysis From the CHAMPION Trials

Abstract Full Text
JAMA Cardiol. 2017;2(2):127-135. doi:10.1001/jamacardio.2016.4556

This exploratory analysis of the 3 CHAMPION trials evaluates the use of cangrelor with glycoprotein IIb/IIIa inhibitors compared with cangrelor alone in patients undergoing percutaneous coronary intervention.

Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection FractionFindings From the American Heart Association Get With The Guidelines–Heart Failure Program

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(2):136-145. doi:10.1001/jamacardio.2016.4726

This study evaluates the clinical predictors of troponin elevation and its association with in-hospital and long-term outcomes among patients with decompensated heart failure with preserved ejection fraction.

Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation

Abstract Full Text
JAMA Cardiol. 2017;2(2):146-152. doi:10.1001/jamacardio.2016.4179

This cohort study examines the association between risk factors for stroke and use vs discontinuation of oral anticoagulation therapy after pulmonary vein isolation among patients with atrial fibrillation.

Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency VirusA Study by the Centers for AIDS Research Network of Integrated Clinical Systems

Abstract Full Text
JAMA Cardiol. 2017;2(2):155-162. doi:10.1001/jamacardio.2016.4494

This cohort study determines whether pooled cohort equations are better at predicting myocardial infarction risk for HIV-positive people than models that incorporate HIV-specific variables.

Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection

Abstract Full Text
open access
JAMA Cardiol. 2017;2(2):163-171. doi:10.1001/jamacardio.2016.4728

This case-control study tests the hypothesis that arterial inflammation is linked to human immunodeficiency virus (HIV) disease activity and to inflammation within HIV-infected lymph nodes.

Resting Heart Rate and Long-term Outcomes Among the African American PopulationInsights From the Jackson Heart Study

Abstract Full Text
JAMA Cardiol. 2017;2(2):172-180. doi:10.1001/jamacardio.2016.3234

This population-based cohort study evaluates the use of the resting heart rate as a prognostic factor for heart failure hospitalization and mortality in African American participants in the Jackson Heart Study.

Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery

Abstract Full Text
JAMA Cardiol. 2017;2(2):181-187. doi:10.1001/jamacardio.2016.4792

This study evaluates national trends in perioperative cardiovascular outcomes and mortality after major noncardiac surgery and identifies surgical subtypes associated with cardiovascular events using a large administrative database of US hospital admissions.

Myocardial Fibrosis Progression in Duchenne and Becker Muscular DystrophyA Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2017;2(2):190-199. doi:10.1001/jamacardio.2016.4801

This randomized clinical trial evaluates the effect of angiotensin-converting enzyme inhibitors on progression of Duchenne and Becker dystrophy in patients with normal left ventricular function.

Brief Report

Association Between Medicare Hospital Readmission Penalties and 30-Day Combined Excess Readmission and Mortality

Abstract Full Text
JAMA Cardiol. 2017;2(2):200-203. doi:10.1001/jamacardio.2016.3704

This study attempts to determine how readmission penalties for hospitals in the United States would change if policy equally weighted 30-day readmissions and mortality from heart failurek, pneumonia, and acute myocardial infarction.

Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart FailureComparison of Machine Learning and Other Statistical Approaches

Abstract Full Text
JAMA Cardiol. 2017;2(2):204-209. doi:10.1001/jamacardio.2016.3956

This registry-based modelling study assesses various approaches to predict all-cause hospital readmissions 30 days after discharge among patients with heart failure.

Invited Commentary

When Does High Risk for Stroke Become Low Risk After Atrial Fibrillation Ablation?

Abstract Full Text
JAMA Cardiol. 2017;2(2):152-154. doi:10.1001/jamacardio.2016.4228

Trends in Perioperative Cardiovascular EventsMostly Sunny, With Showers

Abstract Full Text
JAMA Cardiol. 2017;2(2):188-189. doi:10.1001/jamacardio.2016.4786
Review

Existing and Emerging Payment and Delivery Reforms in Cardiology

Abstract Full Text
JAMA Cardiol. 2017;2(2):210-217. doi:10.1001/jamacardio.2016.3965

This review examines why cardiologists must understand new fee-for-service payment models to coordinate quality care between physicians and specialists and be successful health system leaders.

JAMA Cardiology Clinical Challenge

A 51-Year-Old Man With Exercise-Induced Syncope

Abstract Full Text
JAMA Cardiol. 2017;2(2):221-222. doi:10.1001/jamacardio.2016.3866

A 51-year-old man with no significant medical history experienced syncope while exercising on the treadmill at the gym. What would you do next?

JAMA Cardiology Clinical Guidelines Synopsis

Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk

Abstract Full Text
JAMA Cardiol. 2017;2(2):218-219. doi:10.1001/jamacardio.2016.4640

These guidelines make recommendations for 4 groups at risk for atherosclerotic cardiovascular disease who should already be receiving statin therapy.

Research Letter

Quality Assessment of 7 Cardiovascular Drugs in 10 Sub-Saharan CountriesThe SEVEN Study

Abstract Full Text
JAMA Cardiol. 2017;2(2):223-225. doi:10.1001/jamacardio.2016.3851

This study investigates the quality of 7 commonly used cardiac drugs in 10 countries of sub-Saharan Africa.

Left Ventricular Dysfunction and Conduction Disturbances in Patients With Myotonic Muscular Dystrophy Type I and II

Abstract Full Text
JAMA Cardiol. 2017;2(2):225-228. doi:10.1001/jamacardio.2016.4145

This study quantitates the baseline prevalence and longitudinal incidence of conduction abnormalities and left ventricular dysfunction during intermediate-term follow-up of a cohort of patients with myotonic muscular dystrophy.

Comment & Response

Appropriate Use of High-Sensitivity Cardiac Troponin Levels in Patients With Suspected Acute Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2017;2(2):228. doi:10.1001/jamacardio.2016.4229

Appropriate Use of High-Sensitivity Cardiac Troponin Levels in Patients With Suspected Acute Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2017;2(2):228-229. doi:10.1001/jamacardio.2016.4249

Appropriate Use of High-Sensitivity Cardiac Troponin Levels in Patients With Suspected Acute Myocardial Infarction—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(2):229-230. doi:10.1001/jamacardio.2016.4256

Errors in ICD-9 Codes and Percentages Reported in Tables

Abstract Full Text
JAMA Cardiol. 2017;2(2):230. doi:10.1001/jamacardio.2016.5225
Editor's Note

Cardiomyopathy in Muscular DystrophyWhen to Treat?

Abstract Full Text
free access
JAMA Cardiol. 2017;2(2):199. doi:10.1001/jamacardio.2016.4910

Evaluating and Improving the Cardiovascular Drug Supply for Better Global Health

Abstract Full Text
free access
JAMA Cardiol. 2017;2(2):225. doi:10.1001/jamacardio.2016.3880
Correction

Incorrect ICD-9 Codes and Percentages

Abstract Full Text
free access
JAMA Cardiol. 2017;2(2):230. doi:10.1001/jamacardio.2016.5452
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2017;2(2):118. doi:10.1001/jamacardio.2016.3630
×